Australia
Austria
Belgium
China
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
India
Ireland
Italy
Japan
Kazakhstan
Latvia
Lithuania
Malaysia
Netherlands
Norway
Poland
Singapore
Slovenia
Spain
Sweden
Switzerland
Thailand
UK
Ukraine
Orion as an investment
Our strategy is focused on building well-being and growth driven by Innovative Medicines, while our diversified and profitable business portfolio provides stable cash flow.
Latest financial release
Stock exchange releases
- 10/28/2026 Orion Group Interim report January–September 2026: Strong financial performance and positive developments in the R&D pipeline
- 10/26/2026 Changes in Orion Group’s Executive Team as of 1 January 2027
- 10/20/2026 Inside information: Orion upgrades full-year outlook for 2026
- 10/7/2026 125,000 Orion Corporation A shares converted into B shares
Press releases
- 10/24/2026 Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
- 10/14/2026 Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026
- 10/6/2026 Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market
- 10/5/2026 Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing
Why Orion:
